Researchers are studying the PBAF complex and its mutations across various cancers to understand their association with immunotherapy response. The PBAF complex, which includes components such as PBRM1, appears to play a role in clear cell renal cell carcinoma and may serve as a predictive biomarker for immunotherapy in multiple cancers. The relationship between PBAF complex mutations and immunotherapy response is being explored through various studies, including analyses of tumor immune microenvironments and genomic data.